<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is clearly related to maternal morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>The most characteristic feature is pregnancy loss; however, several other serious complications had been reported including fetal growth restriction, uteroplacental insufficiency, <z:e sem="disease" ids="C0015930" disease_type="Disease or Syndrome" abbrv="">fetal distress</z:e>, pre-<z:hpo ids='HP_0100601'>eclampsia</z:hpo>, and <z:e sem="disease" ids="C0162739" disease_type="Disease or Syndrome" abbrv="HELLP">HELLP syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Herein, we review the different aspects of obstetric APS features, with special emphasis on its life-threatening variant known as catastrophic APS (Asherson's syndrome) and its relationship with a <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> such as <z:e sem="disease" ids="C0162739" disease_type="Disease or Syndrome" abbrv="HELLP">HELLP syndrome</z:e> </plain></SENT>
</text></document>